Pediatric COVID vaccination clinical trial

This pediatric clinical trial aims to test the safety, tolerability and immunogenicity of Pfizer’s COVID vaccine in children under 12 years of age


Obtain the necessary information to complete the technical data sheet of these vaccines and to have all the safety rigour on how they work so that, if necessary, the paediatric population can be vaccinated with the same guarantees as adults. »

Description of Study:

  • Title: Pediatric clinical trial of Pfizer’s COVID vaccine in children under 12 years of age.
  • Principal Investigador: Federico Martinón Torres.
  • Centres of implementation: Global clinical trial involving the Hospital Clínico Universitario de Santiago.
  • Study population: Children under 12 years of age will participate. The clinical trial at the Hospital Clínico Universitario de Santiago will involve 55 healthy children who will take part in the global study, which is expected to include 4,644 young people, 557 of them in Spain.
  • Type of study: Double-blind clinical trial.
  • Methods: Participants will receive an injection approximately 3 weeks apart and those receiving placebo (one third) will have the opportunity to receive the vaccine within the study. Follow-up visits are scheduled and there will be a two-year follow-up period for each child.

Objectives of the Study:

Principal Objective: To evaluate the safety, tolerability and immunogenicity of the Pfizer-BioNTech COVID-19 vaccine in the prevention of COVID-19 in healthy children under 12 years of age.

More about this Study:

The Complejo Hospitalario Universitario de Santiago de Compostela belongs to the Galician network of public use of the Galician Health Service and brings together the four hospitals located in Santiago de Compostela: Hospital Clínico Universitario, Hospital Médico Quirúrgico de Conxo, Hospital Gil Casares and Hospital Psiquiátrico de Conxo.

Plogo Servizo

Other Clinical Trials:

Un bain de bouche antiviral et COVID-19

L’utilisation d’un bain de bouche contenant de la β-cyclodextrine et du citrox (bioflavonoïdes) (CDCM), disponible en pharmacie, permet de réduire la charge virale du SRAS-CoV-2 dans la salive.

Influence du sexe sur les anticorps neutralisants contre le SARS-CoV-2

Cette étude vise à déterminer les différences dans l’évolution de la réponse immunitaire dans les mois qui suivent l’infection par le SARS-CoV-2 chez les hommes et les femmes.

Diagnose

COVIDAir : une nouvelle technologie pour détecter les patients COVID-19

Cette étude vise à déterminer la validité d’une nouvelle méthode de détection du COVID-19 par la caractérisation des molécules présentes dans l’air expiré.

ANTICOV Study : COVID-19 en Afrique

Collaborez avec l’étude ANTICOV et contribuez à traiter la COVID-19 en Afrique.

Progestérone pour traiter le COVID-19

Est-ce que les hormones sexuelles peuvent aider les hommes survivre le COVID-19 ? Cette étude a pour objectif évaluer la sécurité et l’efficacité de la progestérone dans le traitement de COVID-19 chez les hommes hospitalisés.

Flower 729514 1920

E-speranza-COVID19 Project

This study aims to demonstrate efficacy of Montelukast for patients with persistent COVID-19 to help them improve their quality of life.

COnV-ert study, convalescent plasma to stop COVID-19

Early administration of convalescent plasma in people over 50 years of age with mild to moderate COVID-19 disease may slow disease progression and decrease the severity of symptoms.

CombivacS

Clinical trial designed to evaluate the safety and immunogenicity of a dose of Comirnaty vaccine (Pfizer) in people who have previously received a dose of Vaxcevria vaccine (AstraZeneca).

Blood Filter for the Treatment of COVID-19

Is removing SARS-CoV-2 from the blood sufficient to decrease the severity of critically ill COVID patients? This clinical trial aims to test the efficacy of a new blood filter for the treatment of COVID-19.

LacCOVID Study

The LacCOVID study has shown that milk from lactating women who have been vaccinated with Pfizer-BioNTech contains specific antibodies against the SARS-CoV-2 coronavirus.